Cerevel Therapeutics announces positive topline results for Tavapadon in phase 3 adjunctive trial for people living with Parkinson’s disease. The TEMPO-3 trial evaluated its efficacy, safety and tolerability met the primary endpoint and key secondary endpoint. The neurotransmitter dopamine is linked to working memory and motor movement, and the loss of dopamine-producing neurons in the brain result in Parkinson’s disease.
Tavapadon is a selective dopamine D1/D5 receptor partial agonist for the improved motor control. While most dopamine agonists target and stimulate D2/D3 dopamine receptors, Tavapadon is the only D1/D5 selective partial agonist in clinical development for PD.
Recherche 
+86 21 5895 0110 
